Discretamine is a tetrahydroprotoberberine alkaloid isolated from Duguetia moricandiana (Annonaceae). In the present study, anti-inflammatory ability of discretamine in a lipopolysaccharide (LPS) stimulated macrophages model was investigated. LPS-induced NO production was reduced by discretamine treatment (100 and 200 µg/mL) around 50%. Furthermore, discretamine (50, 100, and 200 µg/mL) treatment down-regulated pivotal inflammatory cytokines levels, such as IL-6 (74.1, 76.6, and 75.1%, respectively), IL1-β (89.4, 87.4, and 71.8%, respectively), and TNF-α (61, 45.2, and 52.6%, respectively) levels. Also, discretamine did not reduce peritoneal macrophage viability. Besides that, in vivo carrageenan-induced paw edema experiments were also carried out. Discretamine treatment (5, 10, and 20 mg/kg) reduced paw edema up to 6h. Taken together, these data demonstrated that discretamine exerted its antiinflammatory effect by down-regulation the levels of TNF-α, IL-6, and IL1-β, and by inhibition of NO release.
Natural products are a continuous source of new lead compounds to treat many diseases [1] . They present several secondary metabolites, including alkaloids, which are nitrogenous compounds with a great structural diversity and several biological activities, including anti-inflammatory effects [2] . Discretamine is a tetrahydroprotoberberine alkaloid ( Figure 1 ) characteristic of species of Annonaceae family, such as Duguetia spp. [3] and Fissistigma glaucescens [4] . This alkaloid presents antinociceptive [5] , antiplatelet aggregation [6] , hypotensive, and vasorelaxant effects [7] . Besides, it is a selective α1D-adrenoceptor and 5-HT receptor antagonist in vascular smooth muscle [4] . It has been reported that many alkaloids are able to reduce inflammatory parameters [8, 9] , thus, in this work we investigated a possible antiinflammatory effect of discretamine. Initially, in vitro assays were performed using peritoneal macrophage culture to assess anti-inflammatory effect of discretamine. Peritoneal macrophages are immune system phagocytic cells, which remove and neutralize cellular debris and harmful agents (e.g., pathogens), armed with numerous pro-and anti-inflammatory mediators that can also positively or negatively regulate immune response generation. Besides, they are useful tools to study inflammatory mediators secretion after pathogen stimulation [10] . In this work, lipopolysaccharide (LPS), a membrane component present in gram negative bacteria, was used as an inflammatory in vitro stimulus to macrophages [11] . LPS stimulation induced an increased (p < 0.001) nitric oxide (NO) macrophage production when compared to basal (non-stimulated) cells (Figure 2(a) ). In addition, discretamine (100 and 200 µg/mL) reduced 50.6% and 59%, respectively, LPS-induced NO production. After LPS challenge, macrophage overexpress inducible nitric oxide synthase (iNOS), which is responsible for NO production during inflammation [12] . Some works have demonstrated that alkaloids are able to inhibit iNOS activity and NO production [13, 14] . Thus, it is possible that discretamine acts similarly to reduce NO levels.
Additionally, discretamine effect on LPS-induced pro-inflammatory cytokines secretion was studied. LPS challenge increased (p < 0.001) IL-6, IL1-β, and TNF-α levels on macrophage supernatant when compared to non-stimulated cells. Discretamine treatment (50, 100, and 200 µg/mL) reduced IL-6 (74.1, 76.6, and 75.1%, respectively), IL1-β (89.4, 87.4, and 71.8%, respectively), and TNFα (61, 45.2, and 52.6%, respectively) levels when compared to LPS group (Figure 2 (b), (c), (d)). These pro-inflammatory cytokines contribute to the course of many inflammatory diseases and, in macrophage, their production is related to toll-like receptor 4/nuclear factor-kappa B (TLR4/NF-κB) signaling, the main pathway triggered by LPS [11] . Alkaloids are able to down-regulate this signaling reducing cytokines production [15, 16] . In this regard, discretamine may be inhibiting this pathway to trigger its antiinflammatory effect. It is noteworthy that the above mentioned discretamine effects are not cell death related, since there was no macrophage viability reduction after discretamine treatment, in the absence or presence of LPS, as demonstrated by MTT test (Figure 3 ). In addition, discretamine treatment itself did not alter NO basal levels nor cytokines secretion ( Figure 2 ).
In vivo studies were also carried out after observed antiinflammatory effects of discretamine in vitro. Carrageenan-induced paw edema model was chosen, since it is an established test to assess new anti-inflammatory drugs. Carrageenan, a polysaccharides isolated from red alga, induces a biphasic edema that develops up to 6 h, followed by a second one that starts at 24 h. The initial phase involves histamine, serotonine, bradykinin, prostaglandins, and NO release, which are responsible for increased vascular permeability. This vascular alteration is followed by cell infiltration, which peaks between 6 and 24h [17] . In our test, discretamine (10 and 20 mg/kg) reduced carrageenan-induced paw edema up to 4h, inhibiting 42 and 62% at 1h, 44 and 67% at 2h, and 49 and 48% at 4h, respectively. At 4h and 6h, discretamine at 5 mg/kg also inhibited paw edema by 59 and 38% (Figure 2 ). This late effect of 5 mg/kg dose could be explained by a possible discretamine slow distribution, and consequently, more time is needed to achieve pharmacological target. On the other hand, discretamine (5, 10, and 20 mg/kg) did not reduce paw edema at 24h, implying a discretamine effect in the inflammation outset. In fact, it was observed that discretamine reduces NO production in vitro, and this mediator is released mainly at first paw edema phase [17] , suggesting that discretamine may reduce paw edema, at least, by NO release inhibition. As expected, standard drug, indomethacin inhibited carrageenan-induced paw edema at all times evaluated.
Additionally, Almeida et al. (2011) [5] demonstrated that discretamine has antinociceptive effect and this could be related to its anti-inflammatory effect here presented, since the authors carried out models of inflammatory pain. Taken together, these data demonstrated that discretamine, a protoberberine alkaloid, presents anti-inflammatory effect in vitro and in vivo models. Thus, after more studies, this alkaloid could be a new lead compound to development of new drug to treat inflammatory diseases.
Experimental

Extraction of discretamine:
Discretamine extraction was performed according to the methodology described by Almeida et al. [5] . After purification, the alkaloid was subjected to identification by 1 H NMR and 13 C and was confirmed as the tetrahydroprotoberberine alkaloid (+)-discretamine through specific rotation (+189, c = 0.06).
Animal: Female Swiss albino mice (6-8 weeks) were obtained from Thomas George animal house of Biotechnology Center (CBiotec, UFPB, João Pessoa, Brazil). Animals were kept under standard laboratory conditions on a constant 12 h light/dark cycle with temperature (21 ± 1 ºC). Food and water were given ad libitum. After manipulation, euthanasia was employed by cervical dislocation. All procedures adopted in this study were approved by Institutional Ethics Committee of Biotechnology Center/UFPB (Protocol: 0301/13).
Peritoneal macrophage elicitation: Peritoneal inflammation was induced by injection of 4 ml of 4% thioglycollate (Sigma Aldrich).
Four days after the i.p. thioglycolate injection, animals were euthanized by cervical dislocation and the peritoneal cavity was washed with 8 mL of PBS (phosphate buffer saline), supplemented with 3% fetal bovine serum (FBS) (Gibco). Cell suspension obtained from peritoneal lavage was centrifuged at 1500 rpm for 5 minutes (4 ºC). After that, supernatant was discarded and the pellet was resuspended in 1 mL of complete RPMI medium. Viable cells were counted with a Neubauer chamber (Hemocytometer L. OptikATC-111020) using Trypan blue solution (Merck) [18] . Macrophages culture: Macrophages were enriched by adherence to plastic. For that, viable peritoneal cells were seeded in 96-well plates at a concentration of 4 × 10 5 cells/well in a final volume of 200 µL and incubated for 24 h with supplemented fetal bovine serum (FBS) culture medium in an atmosphere of 5% CO 2 at 37 ºC. Then, nonadherent cells were removed by aspiration. Remaining cells were further incubated for 24 h with complete RPMI medium supplemented or not with LPS (1 µg/mL) (Sigma Aldrich), in the presence and absence of different discretamine concentrations (50, 100, and 200 µg/mL). After 24 hours of culture, the supernatant was collected to quantify the levels of nitric oxide and cytokines [18] .
Analysis of macrophage viability:
Cell viability was estimated by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide) assay. For that, 100 µL of RPMI medium containing 10 µL of MTT solution (5 mg/mL of MTT in PBS) was added to each well. After 4 h of incubation, MTT-containing medium was removed and the precipitate was solubilized in DMSO solution (100 µL). The optical density was read at 570 nm using a microplate spectrophotometer [18] .
Measurement of nitric oxide:
The culture supernatant was analyzed for nitrite production by the Griess reaction, as a measurement of nitric oxide production [19] . For that, 50 µL of samples were incubated with 50 µL of Griess reagent (sulfanilamide and N-1naphthylethylenediamine dihydrochloride) at room temperature for 10 min. The absorbance was measured at 540 nm [18] .
Measurement of cytokines levels by an enzyme-linked immunosorbent assay (ELISA):
TNF-, IL-6, and IL-1β levels in the culture supernatant were evaluated by mouse specific sandwich ELISA, according to the manufacturer's instructions (eBioScience). Optical density was read using a microplate spectrophotometer (450 nm).
Carrageenan-induced paw edema:
To induce inflammation, mice received intraplantar injection in the plantar surface of carrageenan (2.5%) in 20 μL of phosphate buffered saline (PBS) in the right (ipsilateral) hindpaw and 20 μL of PBS in the left (contralateral) hindpaw. Discretamine treatment (5, 10, and 20 mg/kg) was injected orally one hour before intraplantar injections of phlogistic agent. Hindpaw edema was measured with a digital micrometer (Instrutemp 070393611) and is expressed as the difference of thickness (mm) between the stimulated and the saline-injected paw. Paw edema was measured 1h, 2h, 4h, 6h, and 24h after carrageenan challenge. Indomethacin (10 mg/kg) was used as anti-inflammatory controls and injected i.p. one hour before intraplantar injection [17] .
Statistical analysis:
All data were expressed as mean ± SEM and analyzed by GraphPad Prism 5.0 software using one-way analysis of variance (ANOVA) followed by Turkey test. Results were considered statistically significant when p < 0.05.
